Vaxart posted a material revenue uptick in QQ4 2024 to $15.19 million, primarily driven by BARDA-related contracts and non-cash royalty revenue from Inavir in Japan, delivering a gross profit of $15.19 million and a gross margin of approximately 92.76%. Despite this top-line strength, the company remains unprofitable at the operating and net levels, reporting an operating loss of $11.49 million and a net loss of $11.99 million for the quarter, with a negative earnings per share of $0.0059. YoY revenue growth of 367.95% and gross profit growth of 642.54% reflect the government-funded revenue mix, while QoQ gains underscore the expanding, but still early-stage, revenue base. Cash and investments totaled about $51.7 million at year-end, with cash at end of period around $25.2 million; combined with a runway into Q4 2025, the liquidity position supports ongoing pipeline work and strategic reviews, albeit with meaningful near-term tailwinds and risks.
Management remains focused on extending the cash runway through partnerships and non-dilutive funding while continuing to advance multiple vaccine programs on its mucosal oral-vaccine platform. The BARDA stop-work order related to the 10,000-participant portion of the COVID-19 program introduces near-term uncertainty and cost containment pressures, including a workforce reduction in early 2025. The Norovirus program remains a meaningful growth vector, with a Phase 1 trial for second-generation constructs initiated and data publications in Science Translational Medicine reinforcing immunogenicity and cross-reactivity. Mid-2025 top-line Norovirus data are anticipated, which could serve as meaningful catalysts if safety and immunogenicity signals translate into protection, while regulatory and competitive dynamics in the broader norovirus space remain a critical risk.
Overall: QQ4 2024 demonstrates a revenue inflection driven by BARDA/royalty streams but underscored by the volatility of government-backed programs and the ongoing need to secure non-dilutive funding and strategic partnerships to sustain longer-term clinical development and manufacturing capabilities.